CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Clinical trials for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Two-Drug combo aims to starve and attack advanced cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of combining two drugs—ziv-aflibercept and pembrolizumab—in people with advanced solid tumors that have spread. Ziv-aflibercept cuts off the tumor's blood supply, while pembrolizumab helps the immune system fight cancer. The s…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:02 UTC
-
PET scans may let melanoma patients stop therapy early
Disease control OngoingThis study tests whether doctors can safely stop standard anti-PD-1 immunotherapy earlier than usual for people with advanced melanoma that cannot be removed surgically. Using PET/CT scans and tumor biopsies as guides, researchers aim to see if shorter treatment still keeps the c…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 26, 2026 08:01 UTC
-
Triple-Drug cocktail shows promise against Hard-to-Treat melanoma
Disease control OngoingThis study tests a combination of three drugs (dabrafenib, trametinib, and navitoclax) in people with BRAF-mutant melanoma or other solid tumors that have spread or cannot be removed by surgery. The goal is to find the best dose and see how well the drugs shrink tumors. About 75 …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:01 UTC
-
New immunotherapy shows promise in preventing melanoma return
Disease control OngoingThis study tested whether the drug pembrolizumab works better than current standard treatments (high-dose interferon or ipilimumab) in preventing melanoma from coming back after surgery. Over 1,300 patients with high-risk stage III or IV melanoma that had been removed took part. …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:54 UTC
-
New combo tackles resistant melanoma
Disease control OngoingThis study tests whether adding an experimental drug (tazemetostat) to the usual two-drug therapy (dabrafenib and trametinib) can help people with advanced melanoma whose cancer has stopped responding to standard treatment. About 16 adults with a specific gene mutation (BRAF V600…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:51 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of sonidegib combined with the immunotherapy pembrolizumab in people with advanced solid tumors that have spread. The goal is to see if this drug pair can shrink tumors or slow their growth. About 36 adults with cancers like m…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 07:24 UTC
-
Which drug order works best for advanced melanoma? major trial reveals answers
Disease control OngoingThis phase III trial tested two different sequences of drugs in 267 people with advanced melanoma that has a BRAF mutation and cannot be removed by surgery. One group started with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib), w…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Immunotherapy timing may boost melanoma outcomes
Disease control OngoingThis phase II trial studies whether giving the immunotherapy drug pembrolizumab both before and after surgery works better than after surgery alone for people with stage III-IV high-risk melanoma. About 313 participants will receive pembrolizumab either before and after surgery o…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for kidney transplant patients facing advanced skin cancer
Disease control OngoingThis early-stage study tests a combination of drugs (tacrolimus, nivolumab, and ipilimumab) in 12 kidney transplant recipients who have advanced skin cancers that cannot be surgically removed. The goal is to see if this treatment can shrink or control the cancer while keeping the…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New combo aims to tame Immunotherapy's side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New hope for brain metastases: targeted radiation may control tumors and save memory
Disease control OngoingThis study looks at whether a focused, one-time radiation treatment called stereotactic radiosurgery (SRS) can control melanoma that has spread to more than 3 spots in the brain, while also protecting memory and thinking skills. About 49 adults with advanced melanoma and multiple…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New drug cocktail shows promise for deadly brain tumors in melanoma patients
Disease control OngoingThis study tests whether combining two or three drugs can shrink or control melanoma that has spread to the brain. The drugs work by blocking tumor growth and helping the immune system attack cancer cells. The trial involves 29 adults with untreated brain metastases and aims to s…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Fiber fuel: could your diet boost cancer immunotherapy?
Knowledge-focused OngoingThis study looks at whether eating a high-fiber diet can change the gut bacteria in people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a period of time. The m…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 08:01 UTC